The BCR-ABL fusion gene, which causes an excess of aberrant white blood cells to be produced, is what distinguishes Chronic Myeloid Leukaemia (CML), a kind of blood cancer. With the development of tyrosine kinase inhibitors (TKIs), the landscape of CML treatment has undergone a significant metamorphosis during the past 20 years. The management of CML has been transformed by these focused medications, and patient prognosis has greatly improved.